This trial is a registrational randomized, open-label, multicenter Phase II/III study designed to evaluate the efficacy and safety of BL-B01D1 in combination with a PD-1/VEGF bispecific antibody in patients with locally advanced or metastatic non-squamous non-small cell lung cancer.
Voluntarily sign the informed consent form and comply with the protocol requirements;
Age ≥ 18 years;
Expected survival time ≥ 3 months;
Patients with locally advanced non-squamous non-small cell lung cancer;
Presence of small cell lung cancer, neuroendocrine carcinoma, sarcomatoid carcinoma components, or squamous carcinoma components exceeding 10%;
Evidence suggesting the presence of EGFR-sensitive mutations, etc.;
Patients who have received prior systemic therapy;
Prior receipt of therapies targeting the mechanism of tumor immunity;
Sichuan Baili Pharmaceutical Co., Ltd.
Lead sponsor
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Collaborator